BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2019 7:22:50 AM | Browse: 825 | Download: 1064
 |
Received |
|
2019-02-20 07:42 |
|
Peer-Review Started |
|
2019-02-20 09:19 |
|
To Make the First Decision |
|
2019-03-07 05:59 |
|
Return for Revision |
|
2019-03-07 06:24 |
|
Revised |
|
2019-03-12 08:21 |
|
Second Decision |
|
2019-03-15 09:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-03-16 22:34 |
|
Articles in Press |
|
2019-03-16 22:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-03-29 03:11 |
|
Publish the Manuscript Online |
|
2019-03-31 07:22 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Review |
| Article Title |
Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto and Tetsuya Nakatsura |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tetsuya Nakatsura, MD, PhD, Doctor, Professor, Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. tnakatsu@east.ncc.go.jp |
| Key Words |
Hepatocellular carcinoma; Cancer immunotherapy; Immune checkpoint inhibitor; Glypican-3; Cancer vaccine; Clinical trials; Cytotoxic T-lymphocytes |
| Core Tip |
Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease, with a poor prognosis. Recent developments and advances in cancer immunotherapy, particularly immune checkpoint inhibitor therapy, could lead to a major paradigm shift in standard HCC therapy. This review aims to provide an overview of novel immunotherapies, including antigen-based immunotherapies such as glypican-3-targeted immunotherapy, and immune checkpoint inhibitor therapy against HCC. It also discusses the future prospects of cancer immunotherapy against HCC. |
| Publish Date |
2019-03-31 07:22 |
| Citation |
Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 |
| URL |
https://www.wjgnet.com/2308-3840/full/v7/i3/80.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v7.i3.80 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
